Ginkgo Bioworks Holdings, Inc.

NYSE DNA

Ginkgo Bioworks Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -278.57%

Ginkgo Bioworks Holdings, Inc. EBITDA Margin is -278.57% for the Trailing 12 Months (TTM) ending September 30, 2024, a -30.90% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Ginkgo Bioworks Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -212.82%, a 68.34% change year over year.
  • Ginkgo Bioworks Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -672.14%, a -662.78% change year over year.
  • Ginkgo Bioworks Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -88.12%.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
NYSE: DNA

Ginkgo Bioworks Holdings, Inc.

CEO Dr. Jason Kelly Ph.D.
IPO Date April 19, 2021
Location United States
Headquarters 27 Drydock Avenue
Employees 1,218
Sector Health Care
Industries
Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email